Sivik Global Healthcare LLC Reduces Stake in Smith & Nephew plc (NYSE:SNN)

Sivik Global Healthcare LLC cut its holdings in shares of Smith & Nephew plc (NYSE:SNN) by 6.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 140,000 shares of the medical equipment provider’s stock after selling 10,000 shares during the quarter. Smith & Nephew comprises approximately 1.8% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 26th biggest position. Sivik Global Healthcare LLC’s holdings in Smith & Nephew were worth $4,360,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in Smith & Nephew during the 3rd quarter worth $792,000. Lorne Steinberg Wealth Management Inc. lifted its stake in shares of Smith & Nephew by 53.6% in the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 231,045 shares of the medical equipment provider’s stock valued at $5,725,000 after purchasing an additional 80,650 shares in the last quarter. Clearbridge Investments LLC acquired a new stake in shares of Smith & Nephew in the first quarter worth $2,612,000. Sanctuary Advisors LLC purchased a new stake in shares of Smith & Nephew in the second quarter worth about $627,000. Finally, Tocqueville Asset Management L.P. raised its stake in shares of Smith & Nephew by 294.9% during the first quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider’s stock valued at $5,692,000 after purchasing an additional 167,599 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SNN shares. Deutsche Bank Aktiengesellschaft lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. StockNews.com lowered shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Berenberg Bank lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Smith & Nephew has a consensus rating of “Hold”.

Smith & Nephew Stock Up 0.4 %

Shares of NYSE:SNN traded up $0.09 on Thursday, reaching $24.71. The company had a trading volume of 35,170 shares, compared to its average volume of 864,674. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $10.80 billion, a P/E ratio of 12.49, a P/E/G ratio of 1.28 and a beta of 0.85. The stock has a 50-day moving average price of $29.00 and a 200 day moving average price of $27.84. Smith & Nephew plc has a twelve month low of $23.65 and a twelve month high of $31.72.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.